Bristol Reports Solid 4Q Results and Positive CheckMate 227 Data, but Some Concerns Still Linger
In tandem with reporting slightly better-than-expected fourth-quarter results, Bristol reported positive Opdivo plus Yervoy data in non-small cell lung cancer (NSCLC) study CheckMate227, supporting our expectation Bristol will gain close to a quarter of the $12 billion NSCLC market. We don’t expect any major changes to our fair value estimate following the data, but the continued strength of Bristol’s positioning in immuno oncology helps reinforce the company’s wide moat.Bristol changed the rul...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.